MYCOPHENOLATE MOFETIL IS A VALID OPTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESISTANT TO TNF-ALPHA INHIBITORS AND CONVENTIONAL IMMUNOSUPPRESSANTS

被引：0
|
作者：
Macaluso, F. S. [1 ]
Maida, M. [2 ]
Renna, S. [1 ]
Orlando, E. [1 ]
Affronti, M. [1 ]
Sapienza, C. [1 ]
Dimarco, M. [1 ]
Orlando, R. [1 ]
Rizzuto, G. [1 ]
Cottone, M. [1 ]
Orlando, A. [1 ]
机构：
[1] Villa Sofia Cervello Hosp, Div Internal Med, Palermo, Italy
[2] Villa Sofia Cervello Hosp, Gastroenterol & Endoscopy Unit, Palermo, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2017年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OC.06.5
引用
收藏
页码：E92 / E93
页数：2
相关论文
共 50 条
  • [1] Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressants
    Macaluso, F. S.
    Maida, M.
    Renna, S.
    Orlando, E.
    Affronti, M.
    Sapienza, C.
    Dimarco, M.
    Orlando, R.
    Rizzuto, G.
    Cottone, M.
    Orlando, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S392 - S392
  • [2] Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants
    Macaluso, Fabio Salvatore
    Maida, Marcello
    Renna, Sara
    Orlando, Emanuele
    Affronti, Marco
    Sapienza, Chiara
    Dimarco, Mariangela
    Orlando, Rosalba
    Rizzuto, Giulia
    Cottone, Mario
    Orlando, Ambrogio
    [J]. DIGESTIVE AND LIVER DISEASE, 2017, 49 (02) : 157 - 162
  • [3] Mycophenolate mofetil: toxicity in patients with inflammatory bowel disease
    [J]. Reactions Weekly, 2002, 908 (1) : 4 - 4
  • [4] Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease
    Skelly, MM
    Logan, RFA
    Jenkins, D
    Mahida, YR
    Hawkey, CJ
    [J]. INFLAMMATORY BOWEL DISEASES, 2002, 8 (02) : 93 - 97
  • [5] TNF-ALPHA GENE POLYMORPHISMS IN ROMANIAN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Dutescu, Irina Monica
    Tieranu, Cristian
    Popa, Luis
    Bojinca, Mihai
    Tieranu, Cristian
    Diculescu, Mircea
    Popa, Olivia
    [J]. HLA, 2019, 93 (05) : 355 - 355
  • [6] Accelerated induction regimens of TNF-alpha inhibitors in patients with inflammatory bowel disease: a scoping review protocol
    Johnston, Amy
    Natarajan, Sabrina
    Hayes, Meghan
    MacDonald, Erika
    Shorr, Risa
    [J]. BMJ OPEN, 2018, 8 (01):
  • [7] A Comparison of Weight Gain in Patients With Inflammatory Bowel Disease Treated With TNF-alpha Inhibitors, Vedolizumab or Ustekinumab
    Stewart, Oliver
    Leben, Arielle
    Axelrad, Jordan
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S399 - S400
  • [8] Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease (IBD)
    Skelly, MM
    Curtis, H
    Jenkins, D
    Hawkey, CJ
    Logan, RFA
    [J]. GUT, 2000, 46 : A21 - A21
  • [9] THE ECONOMIC REASON FOR THE USE OF VEDOLIZUMAB COMPARED WITH INHIBITORS OF TNF-ALPHA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON THE EXAMPLE OF MOSCOW
    Kornilova, E.
    Poliakova, K.
    Ermolaeva, T.
    Davydovskaya, M.
    Ermolaeva, A.
    Fisun, A.
    [J]. VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [10] Toxicity of mycophenolate mofetil (MMF) in patients with inflammatory bowel disease (IBD).
    Skelly, MM
    Curtis, H
    Jenkins, D
    Hawkey, CJ
    Logan, RF
    [J]. GASTROENTEROLOGY, 2000, 118 (04) : A789 - A789
12345